RecruitingNot ApplicableNCT06424015

Insulin and Insulin Pulses During Fasting

Effect of Insulin and Insulin Pulses on Fasting Glucagon Secretion and on Glucose Metabolism in Subjects Without Type 2 Diabetes


Sponsor

Mayo Clinic

Enrollment

60 participants

Start Date

Sep 15, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.


Eligibility

Min Age: 25 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how the body produces insulin in pulses (bursts) during fasting, and how glucose (blood sugar) metabolism changes in people who have early signs of blood sugar problems — specifically prediabetes or elevated fasting glucose — but do not yet have full diabetes. **You may be eligible if...** - You have normal or slightly elevated fasting blood sugar (prediabetes range) - You have normal or mildly impaired glucose tolerance **You may NOT be eligible if...** - Your HbA1c (a measure of average blood sugar) is above 6.5% (which would indicate diabetes) - Your BMI is 35 or above - You are taking any blood sugar-lowering medication (including metformin) - You are pregnant - You have had upper abdominal surgery (like gastric banding) - You have an active illness or cancer - You have a blood disorder (low hematocrit) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERIntralipid and heparin

Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance

OTHERSaline

Saline will be infused


Locations(1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06424015


Related Trials